MCID: TXP001
MIFTS: 60

Toxoplasmosis

Categories: Blood diseases, Eye diseases, Fetal diseases, Immune diseases, Infectious diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Toxoplasmosis

MalaCards integrated aliases for Toxoplasmosis:

Name: Toxoplasmosis 12 73 54 42 3 44 15 17 70 32
Multisystemic Disseminated Toxoplasmosis 70
Disseminated Toxoplasmosis 12

Classifications:



External Ids:

Disease Ontology 12 DOID:9965
ICD9CM 34 130
MeSH 44 D014123
NCIt 50 C3418
SNOMED-CT 67 266225001
ICD10 32 B58 B58.8 B58.9
UMLS 70 C0040558 C0343816

Summaries for Toxoplasmosis

MedlinePlus : 42 Toxoplasmosis is a disease caused by the parasite Toxoplasma gondii. More than 60 million people in the U.S. have the parasite. Most of them don't get sick. But the parasite causes serious problems for some people. These include people with weak immune systems and babies whose mothers become infected for the first time during pregnancy. Problems can include damage to the brain, eyes, and other organs. You can get toxoplasmosis from Waste from an infected cat Eating contaminated meat that is raw or not well cooked Using utensils or cutting boards after they've had contact with contaminated raw meat Drinking infected water Receiving an infected organ transplant or blood transfusion Most people with toxoplasmosis don't need treatment. There are drugs to treat it for pregnant women and people with weak immune systems. Centers for Disease Control and Prevention

MalaCards based summary : Toxoplasmosis, also known as multisystemic disseminated toxoplasmosis, is related to ocular toxoplasmosis and congenital toxoplasmosis, and has symptoms including fever and pruritus. An important gene associated with Toxoplasmosis is CD40LG (CD40 Ligand), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Valproic acid and Sulfadiazine have been mentioned in the context of this disorder. Affiliated tissues include eye, lymph node and bone marrow, and related phenotypes are Increased viability with MLN4924 (a NAE inhibitor) and Increased viability with MLN4924 (a NAE inhibitor)

Disease Ontology : 12 A coccidiosis that has material basis in protozoan Toxoplasma gondii. The parasite effects most genera of warm-blooded animals, including humans, but the primary host is the felid (cat) family. Animals are infected by eating infected meat, by ingestion of feces of a cat that has itself recently been infected, or transmission by mother to fetus. The symptoms include bilateral, nontender cervical or axillary lymphadenopathy, fever, malaise, myalgia, hepatosplenomegaly, anemia and leukopenia.

CDC : 3 Toxoplasmosis is considered to be a leading cause of death attributed to foodborne illness in the United States. More than 40 million men, women, and children in the U.S. carry the Toxoplasma parasite, but very few have symptoms because the immune system usually keeps the parasite from causing illness.However, women newly infected with Toxoplasma during or shortly before pregnancy and anyone with a compromised immune system should be aware that toxoplasmosis can have severe consequences. Toxoplasmosis is considered one of the neglected parasitic infections of the United States, a group of five parasitic diseases that have been targeted by CDC for public health action.

Wikipedia : 73 Toxoplasmosis is a parasitic disease caused by Toxoplasma gondii, an apicomplexan. Infections with... more...

Related Diseases for Toxoplasmosis

Diseases in the Toxoplasmosis family:

Congenital Toxoplasmosis

Diseases related to Toxoplasmosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1113)
# Related Disease Score Top Affiliating Genes
1 ocular toxoplasmosis 33.2 CD79A CD40LG CCR5
2 congenital toxoplasmosis 33.0 NLRP1 MYD88 IL10 HLA-DQB1 HLA-DQA1 CD79A
3 chorioretinitis 31.7 TNF IL6 IL1B IL10 IFNG
4 posterior uveitis 31.2 TNF IL6 IL4 IFNG
5 uveitis 31.2 TNF IL6 IL4 IL1B IL10 IFNG
6 acquired immunodeficiency syndrome 31.1 TNF IL6 IL1B IL10 IFNG CD79A
7 choroiditis 31.1 TNF IL10 IFNG
8 encephalitis 31.0 TNF TLR2 IL6 IL1B IL10 CCR5
9 vasculitis 31.0 TNF IL6 CD79A CD40LG
10 lymphadenitis 30.9 TNF TLR4 MYD88 IL1B IL10 IFNG
11 meningoencephalitis 30.9 TNF IL6 IL10 CD79A CD40LG
12 syphilis 30.9 TNF IL6 IFNG CD79A CD40LG CCR5
13 exanthem 30.8 TNF IL6 IL1B IL10 IFNG
14 retinal detachment 30.8 TNF TGFB1 IL6 IL10 IFNG
15 histoplasmosis 30.8 TNF STAT1 IFNG HLA-DQA1
16 pneumocystosis 30.8 TNF IL6 DHFR CD40LG CCR5
17 iridocyclitis 30.8 TNF TLR4 IL6 IL1B IL10
18 myositis 30.8 TNF IL6 IL1B IFNG HLA-DQA1
19 panuveitis 30.7 TNF IL6 IL10 HLA-DQB1
20 cryptosporidiosis 30.7 IFNG DHFR CD79A CD40LG
21 myelitis 30.7 TNF IL6 IL10
22 central nervous system lymphoma 30.7 MYD88 IL6 IL10
23 cryptococcosis 30.6 TNF IL4 IL10 IFNG
24 human immunodeficiency virus type 1 30.6 TNF STAT1 IL10 IFNG CD40 CCR5
25 scleritis 30.6 TNF IL4 IFNG
26 progressive multifocal leukoencephalopathy 30.6 TNF STAT1 CD40LG
27 schistosomiasis 30.6 TNF IL4 IL10 IFNG CD40LG
28 pericarditis 30.6 TNF IL6 IL1B IFNG
29 eye disease 30.5 TNF IL6 IL4 IL1B IL10 IFNG
30 lymphopenia 30.5 IL6 IL4 IL10 IFNG
31 cytomegalovirus retinitis 30.5 TNF IL10 IFNG HLA-DQB1 CCR5
32 listeriosis 30.5 TNF TLR2 MYD88 IL6 IL1B IL10
33 tuberculous meningitis 30.5 TNF TLR2 TGFB1
34 graft-versus-host disease 30.5 TNF IL6 IL1B IL10 IFNG HLA-DQB1
35 neutropenia 30.5 TNF IL6 IL1B IL10
36 central nervous system disease 30.4 TNF IL6 IL1B IFNG CCR5
37 chickenpox 30.4 TNF STAT1 IL6 IL4 IL10 IFNG
38 acute graft versus host disease 30.4 TNF IL4 IL10 IFNG
39 sarcoidosis 1 30.4 TNF STAT1 IL1B IFNG HLA-DQB1 CCR5
40 macular retinal edema 30.4 TNF IL6 IL1B
41 herpes zoster 30.4 TNF TLR2 IL10 IFNG DHFR CCR5
42 myocarditis 30.4 TNF TLR4 IL6 IL4 IL1B IL10
43 hemolytic anemia 30.4 TNF IL4 IL10 IFNG CD40LG
44 encephalomalacia 30.4 TNF IL6 IL1B
45 rubella 30.4 TNF TLR4 IL6 IL4 IL1B IL10
46 brucellosis 30.3 TNF TLR4 TGFB1 IL6 IL4 IL10
47 acute disseminated encephalomyelitis 30.3 IL1B IL10 HLA-DQB1 HLA-DQA1
48 echinococcosis 30.3 TNF TLR4 TLR2 IL6 IL10 IFNG
49 amebiasis 30.3 TNF TLR2 IL4 IL1B IL10 CD79A
50 endophthalmitis 30.3 TNF TLR2 IL6 IL1B

Graphical network of the top 20 diseases related to Toxoplasmosis:



Diseases related to Toxoplasmosis

Symptoms & Phenotypes for Toxoplasmosis

UMLS symptoms related to Toxoplasmosis:


fever; pruritus

GenomeRNAi Phenotypes related to Toxoplasmosis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-1 9.73 DHFR HLA-DQB1
2 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-2 9.73 CD40LG DHFR IL10 IL1B MYD88 NLRP1
3 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 9.73 CD40 DHFR
4 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.55 CD40LG IL10 IL1B MYD88 NLRP1 STAT1
5 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.55 HLA-DQB1 IL10 IL1B MYD88 NLRP1 STAT1
6 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-3 9.55 DHFR

MGI Mouse Phenotypes related to Toxoplasmosis:

46 (show all 20)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.55 ALOX12 CCR5 CD40 CD40LG CD79A DHFR
2 immune system MP:0005387 10.52 ALOX12 CCR5 CD40 CD40LG CD79A DHFR
3 homeostasis/metabolism MP:0005376 10.51 ALOX12 CCR5 CD40 CD40LG CD79A DHFR
4 cellular MP:0005384 10.46 CCR5 CD40LG CD79A DHFR HLA-DQB1 IFNG
5 cardiovascular system MP:0005385 10.44 CCR5 CD40LG DHFR HLA-DQB1 IFNG IL10
6 endocrine/exocrine gland MP:0005379 10.38 CD40 CD40LG HLA-DQA1 HLA-DQB1 IFNG IL10
7 mortality/aging MP:0010768 10.38 CCR5 CD40LG CD79A DHFR HLA-DQB1 IFNG
8 growth/size/body region MP:0005378 10.37 DHFR HLA-DQB1 IFNG IL10 IL1B IL4
9 digestive/alimentary MP:0005381 10.35 CCR5 HLA-DQB1 IFNG IL10 IL4 IL6
10 liver/biliary system MP:0005370 10.34 CCR5 CD79A DHFR HLA-DQB1 IFNG IL10
11 nervous system MP:0003631 10.33 CCR5 CD40 CD40LG CD79A DHFR HLA-DQB1
12 integument MP:0010771 10.32 ALOX12 CD40LG DHFR IFNG IL10 IL1B
13 neoplasm MP:0002006 10.21 CCR5 CD79A IFNG IL10 IL1B IL6
14 muscle MP:0005369 10.2 CCR5 DHFR HLA-DQB1 IFNG IL10 IL6
15 renal/urinary system MP:0005367 10.06 CD40 CD40LG CD79A HLA-DQB1 IFNG IL4
16 normal MP:0002873 10.02 CD40 CD79A HLA-DQB1 IFNG IL10 IL4
17 reproductive system MP:0005389 10 CCR5 CD40LG HLA-DQB1 IFNG IL10 IL4
18 respiratory system MP:0005388 9.93 CCR5 HLA-DQB1 IFNG IL10 IL4 IL6
19 skeleton MP:0005390 9.77 CD40 CD40LG IFNG IL10 IL1B IL4
20 vision/eye MP:0005391 9.32 CCR5 IFNG IL10 IL4 IL6 MYD88

Drugs & Therapeutics for Toxoplasmosis

Drugs for Toxoplasmosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 67)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
2
Sulfadiazine Approved, Investigational, Vet_approved Phase 4 68-35-9 5215
3
Spiramycin Approved Phase 4 24916-50-5
4
leucovorin Approved Phase 4 58-05-9 6006
5 Neurotransmitter Agents Phase 4
6 Anticonvulsants Phase 4
7 Trace Elements Phase 4
8 Nutrients Phase 4
9 Micronutrients Phase 4
10 Folic Acid Antagonists Phase 4
11 Vitamins Phase 4
12 Anti-Infective Agents Phase 4
13 Anti-Bacterial Agents Phase 4
14 Antidotes Phase 4
15 Antimalarials Phase 4
16 Antiparasitic Agents Phase 4
17 Antiprotozoal Agents Phase 4
18 Calcium, Dietary Phase 4
19 Protective Agents Phase 4
20
Calcium Nutraceutical Phase 4 7440-70-2 271
21
Levoleucovorin Approved, Investigational Phase 3 68538-85-2 149436
22
Pyrimethamine Approved, Investigational, Vet_approved Phase 3 58-14-0 4993
23
Sulfamethoxazole Approved Phase 3 723-46-6 5329
24
Trimethoprim Approved, Vet_approved Phase 3 738-70-5 5578
25
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
26 Vitamin B9 Phase 3
27 Vitamin B Complex Phase 3
28 Folate Phase 3
29 Cytochrome P-450 Enzyme Inhibitors Phase 3
30 Hematinics Phase 3
31
Atovaquone Approved Phase 2 95233-18-4 74989
32
Clarithromycin Approved Phase 2 81103-11-9 84029
33
Clindamycin Approved, Vet_approved Phase 2 18323-44-9 29029
34
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
35
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
36 Cytochrome P-450 CYP3A Inhibitors Phase 2
37 Hormones Phase 2
38 Clindamycin phosphate Phase 2
39 Clindamycin palmitate Phase 2
40 Trimethoprim, Sulfamethoxazole Drug Combination Phase 2
41 Gastrointestinal Agents Phase 2
42 Antiemetics Phase 2
43 Hormone Antagonists Phase 2
44 glucocorticoids Phase 2
45 Antineoplastic Agents, Hormonal Phase 2
46
protease inhibitors Phase 2
47 BB 1101 Phase 2
48 Anti-Inflammatory Agents Phase 2
49 HIV Protease Inhibitors Phase 2
50
Zidovudine Approved Phase 1 30516-87-1 35370

Interventional clinical trials:

(show all 30)
# Name Status NCT ID Phase Drugs
1 Pilot Trial of Valproate as Adjunctive Treatment for Toxoplasma Gondii Completed NCT02011750 Phase 4 Sodium Valproate treatment;Placebo
2 Phase IV Randomized Study of Pyrimethamine, Sulfadiazine, and Leucovorin Calcium for Congenital Toxoplasmosis Recruiting NCT00004317 Phase 4 Leucovorin calcium;Pyrimethamine;Spiramycin;Sulfadiazine
3 Multicentre, Randomised Study to Determine the Relative Efficacy of Two Therapeutic Strategies in the Treatment of Children With Congenital Toxoplasmosis Unknown status NCT01202500 Phase 3
4 Influence of Trimethoprim-sulfamethoxazole for the Recurrence of Retinochoroiditis Toxoplasma Gondii Completed NCT01449877 Phase 3 Trimethoprim-Sulfamethoxazole
5 Multicenter, Randomized Clinical Trial to Compare the Efficacy and Tolerance of Prenatal Therapy With Pyrimethamine + Sulfadiazine vs Spiramycine to Reduce Vertical Transmission of Toxoplasma Gondii Following Primary Infection in Pregnancy Completed NCT01189448 Phase 3 Pyrimethamine/Sulfadiazine;Spiramycine
6 Effect of Add-on Anti-Toxoplasmosis Treatment on Parameters Defining Toxoplasma Gondii Infection and on Psychopathology in Patients With Schizophrenia or Major Depression Serologically Positive for Toxoplasma Gondii - Phase 3 Study Completed NCT00300404 Phase 3 daraprim;pyrimethamine;folinic acid
7 Primary Prophylaxis of Cerebral Toxoplasmosis in HIV-Infected Patients Completed NCT00000643 Phase 2 Pyrimethamine;Leucovorin calcium
8 Phase II Randomized Open-Label Trial of Atovaquone Plus Pyrimethamine and Atovaquone Plus Sulfadiazine for the Treatment of Acute Toxoplasmic Encephalitis Completed NCT00000794 Phase 2 Sulfadiazine;Clarithromycin;Atovaquone;Pyrimethamine;Leucovorin calcium
9 Adjunctive Dexamethasone for Cerebral Toxoplasmosis: a Double-blinded Randomized Controlled Trial Not yet recruiting NCT04341155 Phase 2 Dexamethasone;Placebo
10 A Single Centre, Open-label, Parallel-group, Single Oral Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Pyrimethamine in Healthy Japanese and Caucasian Male Subjects Completed NCT03258762 Phase 1 Pyrimethamine;Calcium folinate
11 Pyrimethamine Pharmacokinetics in HIV Positive Patients Seropositive for Toxoplasma Gondii Completed NCT00000973 Phase 1 Pyrimethamine;Leucovorin calcium;Zidovudine
12 A Dose-Escalation, Phase I/II Study of Oral Azithromycin and Pyrimethamine for the Treatment of Toxoplasmic Encephalitis in Patients With AIDS Completed NCT00000966 Phase 1 Azithromycin;Pyrimethamine;Leucovorin calcium
13 The Influence of Atazanavir-ritonavir and Efavirenz on Atovaquone Pharmacokinetics in HIV-infected Volunteers Completed NCT01479361 Phase 1 Atovaquone 750 mg twice daily;Atovaquone 1500 mg twice daily
14 TOXODIAG: New Diagnostic Approach for Congenital Toxoplasmosis Unknown status NCT03385499
15 A Pilot Study of 566C80 for the Salvage Treatment of Toxoplasmic Encephalitis in Patients Infected With the Human Immunodeficiency Virus (HIV) Who Have Failed or Are Intolerant of Pyrimethamine-Sulfadiazine Completed NCT00001994 Atovaquone
16 A Pilot Study of Oral Clindamycin and Pyrimethamine for the Treatment of Toxoplasmic Encephalitis in Patients With AIDS Completed NCT00000674 Pyrimethamine;Leucovorin calcium;Clindamycin
17 Comparison of Immunoblotting (IgA and IgG) and the Goldmann-Witmer Coefficient for Diagnosis of Ocular Toxoplasmosis in Immunocompetent Patients Completed NCT03948750
18 Toxoplasmic Encephalitis in Patients With AIDS. Treatment and Prevention of Relapse Completed NCT00002064 Pyrimethamine;Clindamycin
19 A Randomized Prospective Study of Pyrimethamine Therapy for Prevention of Toxoplasmic Encephalitis in HIV-Infected Individuals With Serologic Evidence of Latent Toxoplasma Gondii Infection Completed NCT00000666 Pyrimethamine
20 Spectral Optical Coherence Tomography Findings in Patients With Ocular Toxoplasmosis : a Retrospective Study Completed NCT04219176
21 Cerebral Toxoplasmosis and AIDS in the French Departments of America (DFA). Diagnostic Contribution of a PCR Assay and Genetic Diversity of Toxoplasma Gondii. Completed NCT00803621
22 Evaluation of Biological Biomarkers Diagnostic of Toxoplasmosis Uveitis Completed NCT02843438 Anti-toxoplasmosis treatment;Anti-inflammatory treatments
23 Intravitreal Bevacizumab in Recalcitrant Inflammatory Ocular Neovascularization: Multicenter Collaborative Study Completed NCT00645697
24 AIDS Defining Opportunistic Infections in Naive HIV Cases Completed NCT03993093
25 Determination of Genetic Susceptibility in Severe Recurrences of Ocular Toxoplasmosis Recruiting NCT02863588
26 Integrating the Diagnosis and Management of HIV-associated Central Nervous System (CNS) Infections Into Routine Health Services in Low and Middle Income Countries (LMICs) Recruiting NCT03226379
27 Lyon Clinical Research Program on Maternal and Congenital Toxoplasmosis Based on the Toxo-Ly Cohort: Risks and Clinical Consequences, Prevention, Diagnosis and Treatment Recruiting NCT02936921
28 Surveillance of Zika-related Microcephaly in Sub-Saharan Africa and Asia Recruiting NCT03922594
29 Diagnosis of Toxoplasma Gondii Infection by Exploration of Cellular Immunity Not yet recruiting NCT04825600
30 Latent Toxoplasmosis in Females With Borderline Personality Disorder - Occurrence, Clinical Features, and Impact on Effectiveness of Combined Pharmacotherapeutic and Psychotherapeutic Treatment Suspended NCT03932656 Psychopharmaceuticals

Search NIH Clinical Center for Toxoplasmosis

Inferred drug relations via UMLS 70 / NDF-RT 51 :


CLINDAMYCIN PHOSPHATE PWDR
TRIMETHOPRIM SULFATE

Cochrane evidence based reviews: toxoplasmosis

Genetic Tests for Toxoplasmosis

Anatomical Context for Toxoplasmosis

MalaCards organs/tissues related to Toxoplasmosis:

40
Eye, Lymph Node, Bone Marrow, T Cells, Placenta, Spinal Cord, Spleen

Publications for Toxoplasmosis

Articles related to Toxoplasmosis:

(show top 50) (show all 15249)
# Title Authors PMID Year
1
Serological survey and risk factors associated with Toxoplasma gondii infection among HIV-infected pregnant women attending Abuja Tertiary Hospital, Nigeria. 61 42
33488988 2020
2
Seroprevalence of toxoplasmosis in pregnant women of the Marrakech-Safi region, Morocco. 61 42
33402893 2020
3
Latent Toxoplasma gondii infections are associated with elevated biomarkers of inflammation and vascular injury. 42
33602170 2021
4
High diagnostic efficiency of IgM-ELISA with the use of multiple antigen peptides (MAP1) from T. gondii ESA (SAG-1, GRA-1 and GRA-7), in acute toxoplasmosis. 54 61
20464125 2010
5
Toxoplasmosis in pregnancy: determination of IgM, IgG and avidity in filter paper-embedded blood. 61 54
19554010 2009
6
Recovery of anti-Toxoplasma gondii immunoglobulin M in stored guthrie card blood spots. 61 54
19494076 2009
7
[Seroprevalence of toxoplasmosis in pregnant women in Rabat, Morocco]. 61 54
17982862 2007
8
Evaluation of a real-time PCR assay based on the repetitive B1 gene for the detection of Toxoplasma gondii in human peripheral blood. 54 61
17385062 2007
9
Reduced risk of toxoplasma encephalitis in HIV-infected patients--a prospective study from Gauteng, South Africa. 54 61
17686219 2007
10
Fast dipstick dye immunoassay for detection of immunoglobulin G (IgG) and IgM antibodies of human toxoplasmosis. 61 54
15643007 2005
11
Targeting DHFR in parasitic protozoa. 54 61
15718161 2005
12
Lacrimal secretory IgA in active posterior uveitis induced by Toxoplasma gondii. 54 61
15761603 2004
13
Synthesis, biological activity and molecular modeling of 6-benzylthioinosine analogues as subversive substrates of Toxoplasma gondii adenosine kinase. 61 54
15055998 2004
14
CD154 activates macrophage antimicrobial activity in the absence of IFN-gamma through a TNF-alpha-dependent mechanism. 61 54
14662879 2003
15
Toxoplasmosis in pregnant Sudanese women. 54 61
12939674 2003
16
[Prospective study of pregnants and babies with risk of congenital toxoplasmosis in municipal district of Rio Grande do Sul]. 61 54
12937726 2003
17
The significance of complement fixation test in clinical diagnosis of toxoplasmosis. 54 61
14594352 2003
18
Immunoglobulin M (IgM)-glycoinositolphospholipid enzyme-linked immunosorbent assay: an immunoenzymatic assay for discrimination between patients with acute toxoplasmosis and those with persistent parasite-specific IgM antibodies. 61 54
11923364 2002
19
Disseminated histoplasmosis presenting as pyoderma gangrenosum-like lesions in a patient with acquired immunodeficiency syndrome. 61 54
11703524 2001
20
Seroepidemiological study of Toxoplasma gondii infection in the human population in the Eastern Region. 61 54
11255603 2001
21
Vitritis as the primary manifestation of ocular syphilis in patients with HIV infection. 54 61
9512147 1998
22
IgM and IgA antibody responses in 12 cases of human acquired toxoplasmosis. 61 54
9674283 1997
23
Diagnosis of toxoplasmosis by joint detection of immunoglobulin A and immunoglobulin M. 61 54
9163460 1997
24
Bicentric evaluation of Access Toxo immunoglobulin M (IgM) and IgG assays and IMx toxo IgM and IgG assays and comparison with Platelia Toxo IgM and IgG assays. 54 61
8784554 1996
25
Diagnostic implications of kinetics of immunoglobulin M and A antibody responses to Toxoplasma gondii. 54 61
8735107 1996
26
The cytogenetic effects of pyrimethamine on male mouse germ cells. 54 61
9216789 1996
27
[Diagnosis of acquired toxoplasmosis using simultaneous determination of specific immunoglobulins M, A and E]. 61 54
7489131 1995
28
Evaluation of risk and diagnostic value of quantitative assays for anti-Toxoplasma gondii immunoglobulin A (IgA), IgE, and IgM and analytical study of specific IgG in immunodeficient patients. 61 54
7790453 1995
29
[Comparative study of the serologic response of IgA and IgM type in the diagnosis of acute toxoplasmosis]. 61 54
7865558 1994
30
[Comparison of the diagnostic usefulness of immunoglobulins A and M in acute toxoplasmosis]. 54 61
8159880 1993
31
[Determination of IgG toxoplasma antibodies using ELISA with uniform serum dilutions]. 54 61
8348624 1993
32
Improved serological diagnosis of Toxoplasma gondii infection by detection of immunoglobulin A (IgA) and IgM antibodies against P30 by using the immunoblot technique. 61 54
1624560 1992
33
No interference of rheumatoid factor(s) with toxoplasmosis IgM determination in infancy. 61 54
1728544 1992
34
Pharmacokinetic justification of antiprotozoal therapy. A US perspective. 54 61
1782741 1991
35
A systematic review and meta-analysis of Toxoplasma gondii in roe deer (Capreolus capreolus) and red deer (Cervus elaphus) in Europe. 61
33164352 2021
36
Cerebral toxoplasmosis with multiple hemorrhage lesions in an HIV infected patient: A case report and literature review. 61
33401016 2021
37
Beneficial effects of Strongyloides venezuelensis antigen extract in acute experimental toxoplasmosis. 61
33247953 2021
38
Immunogenicity of in-silico designed multi-epitope DNA vaccine encoding SAG1, SAG3 and SAG5 of Toxoplasma gondii adjuvanted with CpG-ODN against acute toxoplasmosis in BALB/c mice. 61
33485872 2021
39
Genotyping of Toxoplasma gondii in a lethal toxoplasmosis outbreak affecting captive howler monkeys (Alouatta sp.). 61
33283281 2021
40
Molecular and serological study on congenital toxoplasmosis in newborn of Shiraz, Southern Iran. 61
33247407 2021
41
The host mTOR pathway and parasitic diseases pathogenesis. 61
33534053 2021
42
Granulomatous amoebic encephalitis caused by Acanthamoeba in a patient with AIDS: a challenging diagnosis. 61
31455179 2021
43
Ocular manifestations in renal allograft recipients: An Indian perspective. 61
33727456 2021
44
First nationwide survey of the seroprevalence of Toxoplasma gondii in wild boars in Japan. 61
33615409 2021
45
Sulfadiazine Hypersensitivity and Desensitization in Children With Congenital Toxoplasmosis: A Report on Two Cases. 61
33181786 2021
46
The activity of the diaminopyrimidine dihydrofolate reducatase inhibitor, iclaprim, against Toxoplasma gondii in an in vitro model: a pilot study. 61
33387894 2021
47
Early immune responses and parasite tissue distribution in mice experimentally infected with oocysts of either archetypal or non-archetypal genotypes of Toxoplasma gondii. 61
33315001 2021
48
Essential Genes of the Parasitic Apicomplexa. 61
33419671 2021
49
Boromycin Has Potent Anti-Toxoplasma and Anti-Cryptosporidium Activity. 61
33468470 2021
50
Screening for common eye diseases in the elderly with Optos ultra-wide-field scanning laser ophthalmoscopy: a pilot study with focus on ocular toxoplasmosis. 61
33725270 2021

Variations for Toxoplasmosis

Expression for Toxoplasmosis

Search GEO for disease gene expression data for Toxoplasmosis.

Pathways for Toxoplasmosis

Pathways related to Toxoplasmosis according to GeneCards Suite gene sharing:

(show top 50) (show all 100)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.11 TNF TLR4 TLR2 TGFB1 STAT1 NLRP1
2
Show member pathways
13.93 TNF TGFB1 STAT1 IL6 IL4 IL1B
3
Show member pathways
13.82 TNF TLR4 TGFB1 IL6 IL4 IL1B
4
Show member pathways
13.62 TNF TGFB1 STAT1 IL6 IL4 IL1B
5
Show member pathways
13.55 TLR4 TLR2 MYD88 HLA-DQB1 HLA-DQA1 CD79A
6
Show member pathways
13.55 TNF TLR4 TLR2 TGFB1 STAT1 MYD88
7
Show member pathways
13.5 TNF TGFB1 STAT1 MYD88 IL6 IL4
8
Show member pathways
13.45 TNF TGFB1 IL6 IL4 IL1B IL10
9
Show member pathways
13.38 TNF TLR4 TLR2 STAT1 MYD88 IL4
10
Show member pathways
13.36 TNF TLR4 TLR2 TGFB1 STAT1 MYD88
11
Show member pathways
13.11 TNF TLR4 TLR2 STAT1 MYD88 IL6
12
Show member pathways
13.08 TNF TLR4 TLR2 STAT1 IL6 IL4
13 13.01 TNF TLR2 STAT1 MYD88 IL6 IL1B
14
Show member pathways
13.01 TNF TLR4 TLR2 STAT1 MYD88 IL6
15
Show member pathways
13.01 TNF TGFB1 STAT1 IL6 IL4 IL1B
16
Show member pathways
12.92 TNF TLR4 TLR2 STAT1 NLRP1 MYD88
17
Show member pathways
12.91 TNF TLR4 TLR2 TGFB1 MYD88 IL6
18
Show member pathways
12.88 TNF TLR4 TLR2 MYD88 IL6 IL1B
19
Show member pathways
12.85 TNF STAT1 IL1B IFNG CD40LG CD40
20
Show member pathways
12.84 TNF IL4 IL10 IFNG HLA-DQB1 HLA-DQA1
21
Show member pathways
12.78 TNF TLR4 TLR2 MYD88 IL1B CD40LG
22
Show member pathways
12.75 TNF STAT1 IL6 IL1B IL10 IFNG
23 12.71 TNF TLR2 STAT1 NLRP1 MYD88 IL4
24
Show member pathways
12.55 STAT1 IL6 IL4 IL10 IFNG
25 12.54 TNF TGFB1 IL6 HLA-DQB1 HLA-DQA1 CD40
26
Show member pathways
12.53 TNF TLR2 IL6 IL4 IL1B IFNG
27
Show member pathways
12.53 TNF TLR4 STAT1 MYD88 IL6 IL1B
28
Show member pathways
12.52 TNF IL6 IL4 IL1B IFNG DHFR
29
Show member pathways
12.48 TNF TGFB1 STAT1 IL6 IL4 IL1B
30 12.47 TNF TLR4 MYD88 IL1B
31
Show member pathways
12.47 TNF TLR4 TLR2 TGFB1 STAT1 IL6
32
Show member pathways
12.46 HLA-DQB1 HLA-DQA1 CD40LG CD40
33 12.46 TNF TLR4 STAT1 NLRP1 MYD88 IL6
34
Show member pathways
12.42 TNF TLR4 TLR2 MYD88 IL6
35
Show member pathways
12.42 TNF STAT1 MYD88 IL6 IL1B IL10
36
Show member pathways
12.41 TNF IL6 IL10 CCR5
37 12.41 TNF TLR4 TLR2 TGFB1 STAT1 IL6
38 12.39 TNF TLR4 TLR2 TGFB1
39
Show member pathways
12.38 TNF TLR4 TLR2 STAT1 MYD88 IL6
40
Show member pathways
12.37 TNF TLR4 STAT1 IL1B IFNG
41 12.31 TNF TLR4 MYD88 IL6 IL1B IL10
42
Show member pathways
12.31 TNF TLR4 TLR2 TGFB1 STAT1 MYD88
43 12.29 TNF TLR4 TLR2 TGFB1 STAT1 MYD88
44 12.28 TNF IL6 IL1B IL10
45 12.25 TLR4 TLR2 HLA-DQB1 HLA-DQA1
46 12.24 HLA-DQB1 HLA-DQA1 CD40LG CD40
47 12.24 TNF TLR4 TGFB1 IL6 IL4 IL1B
48 12.23 TNF TGFB1 STAT1 IL1B IFNG
49 12.22 TNF IL6 IL4 IL10 IFNG CD79A
50 12.21 TNF TGFB1 STAT1 IL6 IL4 IL1B

GO Terms for Toxoplasmosis

Cellular components related to Toxoplasmosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.81 TNF TGFB1 IL6 IL4 IL1B IL10
2 external side of plasma membrane GO:0009897 9.43 TNF TLR4 CD79A CD40LG CD40 CCR5
3 cell surface GO:0009986 9.17 TNF TLR4 TLR2 TGFB1 CD40LG CD40

Biological processes related to Toxoplasmosis according to GeneCards Suite gene sharing:

(show top 50) (show all 105)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.4 TLR4 TLR2 STAT1 MYD88 IL6 IL4
2 positive regulation of transcription by RNA polymerase II GO:0045944 10.3 TNF TLR4 TLR2 TGFB1 STAT1 IL6
3 immune system process GO:0002376 10.25 TLR4 TLR2 NLRP1 MYD88 HLA-DQB1 HLA-DQA1
4 positive regulation of transcription, DNA-templated GO:0045893 10.24 TNF TGFB1 STAT1 IL6 IL4 IL1B
5 positive regulation of cell proliferation GO:0008284 10.22 TGFB1 STAT1 IL6 IL4 IL1B IFNG
6 negative regulation of apoptotic process GO:0043066 10.21 MYD88 IL6 IL4 IL10 CD40LG ALOX12
7 negative regulation of cell proliferation GO:0008285 10.17 TLR2 TGFB1 IL6 IL1B IL10
8 positive regulation of gene expression GO:0010628 10.16 TNF TLR4 TLR2 TGFB1 MYD88 IL6
9 defense response to bacterium GO:0042742 10.12 TNF TLR4 NLRP1 MYD88 IL10
10 defense response to virus GO:0051607 10.09 STAT1 NLRP1 IL6 IFNG CD40
11 positive regulation of protein phosphorylation GO:0001934 10.09 TNF TGFB1 IL1B IFNG CD40
12 cytokine-mediated signaling pathway GO:0019221 10.09 TNF TGFB1 STAT1 MYD88 IL6 IL4
13 regulation of cell proliferation GO:0042127 10.08 TNF TGFB1 STAT1 MYD88
14 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 10.07 TNF TLR4 MYD88 CD40
15 response to lipopolysaccharide GO:0032496 10.06 TLR4 TLR2 MYD88 IL1B IL10
16 tumor necrosis factor-mediated signaling pathway GO:0033209 10.03 TNF STAT1 CD40LG CD40
17 positive regulation of DNA-binding transcription factor activity GO:0051091 10.03 TNF IL6 IL1B IL10
18 defense response to Gram-positive bacterium GO:0050830 10.02 TNF TLR2 MYD88 IL6
19 positive regulation of inflammatory response GO:0050729 10.01 TNF TLR4 TLR2 IL1B IFNG
20 regulation of inflammatory response GO:0050727 10 TNF TLR4 NLRP1 MYD88
21 positive regulation of JNK cascade GO:0046330 10 TNF TLR4 MYD88 IL1B
22 positive regulation of tumor necrosis factor production GO:0032760 10 TLR4 TLR2 MYD88 IL6 IFNG
23 B cell differentiation GO:0030183 9.99 IL4 IL10 CD79A CD40LG
24 cellular response to mechanical stimulus GO:0071260 9.99 TLR4 TGFB1 MYD88 IL1B CD40
25 regulation of insulin secretion GO:0050796 9.98 TNF IL6 IL1B IFNG
26 interferon-gamma-mediated signaling pathway GO:0060333 9.98 STAT1 IFNG HLA-DQB1 HLA-DQA1
27 cellular response to organic cyclic compound GO:0071407 9.97 TNF TGFB1 STAT1 IL1B
28 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.97 TNF TLR4 TLR2 IL1B
29 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.97 TNF IL6 IL4 IFNG CD40
30 negative regulation of tumor necrosis factor production GO:0032720 9.96 TLR4 IL4 IL10
31 negative regulation of interleukin-6 production GO:0032715 9.96 TNF TLR4 IL10
32 positive regulation of T cell proliferation GO:0042102 9.96 IL6 IL4 IL1B CD40LG
33 positive regulation of smooth muscle cell proliferation GO:0048661 9.96 TNF STAT1 MYD88 IL6 ALOX12
34 response to glucocorticoid GO:0051384 9.95 TNF IL6 IL10
35 positive regulation of interferon-gamma production GO:0032729 9.95 TNF TLR4 IL1B
36 positive regulation of interleukin-8 production GO:0032757 9.95 TNF TLR4 TLR2 MYD88 IL6 IL1B
37 positive regulation of interleukin-6 production GO:0032755 9.95 TNF TLR4 TLR2 MYD88 IL6 IL1B
38 positive regulation of MAP kinase activity GO:0043406 9.94 TNF TGFB1 CD40
39 humoral immune response GO:0006959 9.94 TNF IL6 IFNG
40 positive regulation of protein complex assembly GO:0031334 9.94 TNF TGFB1 IFNG
41 positive regulation of cytokine production GO:0001819 9.94 TNF IL10 IFNG
42 negative regulation of fat cell differentiation GO:0045599 9.94 TNF TGFB1 IL6
43 positive regulation of blood vessel endothelial cell migration GO:0043536 9.94 TGFB1 CD40 ALOX12
44 positive regulation of nitric oxide biosynthetic process GO:0045429 9.94 TNF TLR4 IL1B IFNG
45 positive regulation of phagocytosis GO:0050766 9.93 TNF IL1B IFNG
46 positive regulation of epithelial to mesenchymal transition GO:0010718 9.93 TGFB1 IL6 IL1B
47 protein kinase B signaling GO:0043491 9.93 TNF TGFB1 IL1B CD40
48 positive regulation of interleukin-1 beta production GO:0032731 9.93 TNF TLR4 NLRP1 IL6 IFNG
49 toll-like receptor signaling pathway GO:0002224 9.92 TLR4 TLR2 MYD88
50 extrinsic apoptotic signaling pathway GO:0097191 9.92 TNF TGFB1 IFNG

Molecular functions related to Toxoplasmosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.16 TNF TLR4 TLR2 TGFB1 STAT1 NLRP1
2 identical protein binding GO:0042802 10.01 TNF TLR4 TLR2 TGFB1 STAT1 MYD88
3 growth factor activity GO:0008083 9.56 TGFB1 IL6 IL4 IL10
4 MHC class II receptor activity GO:0032395 9.43 HLA-DQB1 HLA-DQA1
5 Toll-like receptor binding GO:0035325 9.37 TLR2 MYD88
6 lipopolysaccharide receptor activity GO:0001875 9.32 TLR4 TLR2
7 cytokine activity GO:0005125 9.23 TNF TGFB1 IL6 IL4 IL1B IL10
8 tumor necrosis factor receptor binding GO:0005164 9.13 TNF STAT1 CD40LG

Sources for Toxoplasmosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....